Chartered Patent Attorney
European Patent Attorney
Fiona graduated with a Masters Degree in Natural Sciences at the University of Cambridge. She specialised in chemistry, physiology and pharmacology. She also obtained her certificate of Intellectual Property Law at Queen Mary University of London.
Fiona joined GJE in 2005. She qualified as both a Chartered Patent Attorney and European Patent Attorney in 2010. She became a partner in 2015.
Fiona is an experienced patent attorney and handles a wide variety of work in the pharmaceutical, chemical and biotechnology fields. The majority of Fiona’s work involves working with UK clients, and she therefore has extensive experience in developing and implementing IP strategies that are aligned with commercial objectives. With that in mind, Fiona has helped develop the firm’s suite of fixed price products known as ConsultIP, in particular the IP Audit, which offers a strategic review of a company’s IP, starting from the business plan. Rather than looking at IP rights in isolation, the IP audit provides a complete review of a company’s IP strategy, and a roadmap for improving it.
Fiona deliberately tries to avoid becoming too focused in a particular sector, believing that the underlying principles of implementing an IP strategy can be applied across many industries, and to business of varying sizes. That said, Fiona is recognised for her expertise in pharmaceutical life cycle management in particular obtaining Supplementary Protection Certificates (SPCs) and Patent Term Extensions for approved drugs in a number of jurisdictions worldwide. She also has a particular interest in second medical use patents, and has helped a number of clients achieve commercial success with re-purposed drugs.
Fiona is a regular attendee at FICPI and AIPLA overseas conferences and also lectures on the CIPA Administrator course. In 2017, Fiona was recognised as one of Management Today’s ’35 under 35′ for her accomplishments in intellectual property. Fiona has successfully guided clients in the Biotechnology and Pharmaceutical industries through multiple fund-raising rounds and partnering successes, helping them raise well in excess of £200 million in investment the last three years alone.